Immupharma PLC Holding(s) in Company (3027G)
June 05 2013 - 2:01AM
UK Regulatory
TIDMIMM TIDMAV.
RNS Number : 3027G
Immupharma PLC
05 June 2013
FOR IMMEDIATE RELEASE 5 JUNE 2013
NOTIFICATION OF AVIVA'S MAJOR INTEREST IN SHARES
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
confirm that its long standing shareholder Aviva plc ("Aviva") and
its subsidiaries has notified the Company that it has recently
increased its shareholding in ImmuPharma Ordinary Shares to
4,388,986 representing a 5.38% shareholding in the Company.
The full TR1 form is shown at the end of this announcement.
Commenting on the announcement, Richard Warr, Chairman said: "We
are pleased to record that Aviva has again demonstrated its support
for ImmuPharma, its assets and long term investment profile."
For further information please see the Group's web site,
www.immupharma.com, or contact:
ImmuPharma PLC (www.immupharma.com)
Richard Warr, Chairman +44 20 7152 4080
Dimitri Dimitriou, Chief Executive
Officer +44 20 7152 4080
Lisa Baderoon, Head of Investor +44 7721 413
Relations 496
Panmure Gordon +44 20 7886 2500
Hugh Morgan, Fred Walsh, Hannah
Woodley
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has recently received the
approval from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. The Company's second
potential blockbuster compound in cancer "IPP-204106" is completing
a new Phase I/ II clinical trial with the next generation of
"polyplexed Nucant". ImmuPharma was founded and is led by a
commercially focused Board and management team with extensive
experience.
Recently ImmuPharma announced that it had secured a GBP50
million, five year Equity Financing Facility ("EFF") with Darwin
Strategic Limited ("Darwin"), a majority owned subsidiary of
Henderson Global Investors' Volantis Capital ("Henderson Volantis")
to fund ImmuPharma's late stage Lupuzor compound.
For more information on ImmuPharma please go to:
www.immupharma.com.
For filings with the FSA include
the annex
For filings with issuer exclude
the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
-----------------------------------------------
1. Identity of the issuer or Immupharma plc
the underlying issuer
of existing shares to which
voting rights are
attached: (ii)
-------------------------------------------------------------- ------------------------------------------
2. Reason for the notification (please tick the appropriate
box or boxes):
----------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
----------------------------------------------------------------- ---------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
----------------------------------------------------------------- ---------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------------- ---------------------------------------
An event changing the breakdown of voting rights
----------------------------------------------------------------- ---------------------------------------
Other (please
specify):
------------------------------------------------------------ --- ---------------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
(iii)
------------------------------------------------------------ --------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):(iv)
BNY Norwich Union Nominees
Limited 352,153*
Chase (GA Group) Nominees
Limited 2,792,276*
Chase Nominees Limited 233,259*
*denotes direct interest
Chase (GA Group) Nominees
Limited 351,098
Chase Nominees Limited 253,918
Vidacos Nominees Limited 406,282
------------------------------------------------------------ --------------------------------------------
5. Date of the transaction 31 May 2013
and date on
which the threshold is crossed
or
reached: (v)
------------------------------------------------------------ --------------------------------------------
6. Date on which issuer notified: 03 June 2013
------------------------------------------------------------ --------------------------------------------
7. Threshold(s) that is/are 3% to 4% change at Direct
crossed or Interest Level and
reached: (vi, vii) <5% to 5% change at Combined
Interest Level
------------------------------------------------------------ --------------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------------ ------------------------------ ----------------------------------------------------------
Number Number Number Number of % of voting
of of of shares voting rights (x)
Shares Voting rights
Rights
------------------ ------------------ ---------- ------------- ----------------------- ------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------------ ------------------ ---------- ------------- ---------- ----------- ------- ---------
Ordinary
Shares
GB0033711010 2,471,621 2,471,621 4,388,986 3,377,688 4.14% 1.24%
------------------ ---------- ------------- ---------- ----------- ------- ---------
1,011,298
------------------ ------------------ ---------- ------------- ---------- ----------- ------- ---------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that rights
(xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
------------------ ------------------ ------------------------- ----------------------- ------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights (xix,
(xvii) period refers to xx)
(xviii)
------------------ --------- ----------- ------------ ------------------- ----------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- -------- ------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
4,388,986 5.38%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
----------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited, with the following
chain of controlled undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
----------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
--------------------------------------------- -----------------------------
11. Number of voting rights proxy
holder will cease
to hold:
--------------------------------------------- -----------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
--------------------------------------------- -----------------------------
13. Additional information: Figures are based the total
number of voting rights of
81,532,463.
--------------------------------------------- -----------------------------
14. Contact name: Tracy Weimar, ImmuPharma
plc
--------------------------------------------- -----------------------------
15. Contact telephone number: 020 7152 4080
--------------------------------------------- -----------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLVZLFBXQFXBBL
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024
